Penalty Amount
$13,670,921
Connecticut joined a coalition of states and the federal government in settling allegations that Takeda paid healthcare providers speaker honoraria and provided meals to induce prescriptions of Trintellix, leading to allegedly false claims to government healthcare programs. Takeda agreed to pay $13,670,921 plus accrued interest, with portions allocated to federal and state programs.
Takeda agreed to pay the federal government and states $13,670,921, plus accrued interest. The settlement allocates $1,703,572 to participating states’ Medicaid programs, including $213,674 to Connecticut’s Medicaid program.
Review healthcare provider, speaker bureau, consulting, and event-services agreements for clear limits on honoraria, meals, travel, and other benefits; documented fair-market-value compensation; legitimate educational purpose requirements; and controls against linking payments to prescribing or referrals. Vendor and customer agreements involving healthcare professional engagement should include approval, recordkeeping, audit, and compliance-certification provisions addressing Anti-Kickback Statute and false-claims risks. This release does not describe a privacy violation, so it does not indicate a specific need to amend data-processing, privacy-notice, or breach-notification clauses.
Entity
Takeda Pharmaceuticals, U.S.A., Inc.
Industry
Healthcare"Takeda Pharmaceuticals, U.S.A., Inc."
"paid the federal government and states $13,670,921 in addition to accrued interest"
"The Anti-Kickback Statute prohibits offering or paying anything of value to induce the referral of items or services covered by Medicare, Medicaid, TRICARE, and other federal health care programs."
"in violation of state false claims statutes."
"Takeda paid improper remuneration, including in the form of speaker honoraria and meals at high-end restaurants, to healthcare professionals to induce them to prescribe the antidepressant medication Trintellix in violation of the Anti-Kickback Statute."
"10/09/2026"
$625K
Connecticut reached a $625,000 settlement with Frontier Communications Parent Inc. over an April 2024 breach in which compromised employee and vendor credentials were used to access internal systems and exfiltrate unencrypted personal information of 58,841 Connecticut residents. The settlement requires Frontier to strengthen its security program, implement specific safeguards and training, and obtain an independent third-party assessment.
$2.6M
Connecticut and New York found that Boston Children’s Health Physicians and its security vendor, XTIUM, failed to use reasonable safeguards, resulting in hackers accessing sensitive personal, medical, and employee information. The companies agreed to pay penalties totaling $2.64 million and implement enhanced cybersecurity measures.
Connecticut joined a coalition of state attorneys general filing a notice in Character Technologies, Inc.’s bankruptcy proceedings, raising concerns about the company’s safety and privacy practices and the sensitive information it holds. The states seek protections for children and consumers if the company’s business or assets are sold or transferred; the filing does not impose a fine or other remedy.
Attorney General William Tong and Consumer Counsel Claire Coleman petitioned PURA to review how Connecticut public utilities use artificial intelligence, citing potential data privacy and cybersecurity risks, algorithmic errors, and misleading outputs. The petition asks PURA to examine utility AI systems, safeguards, vendors, and data security practices; it does not report a finding of violation or an imposed penalty.
$2.0M
Connecticut Attorney General William Tong announced a settlement with RZ Smoke, Inc. over allegations that it distributed and sold high-potency cannabis products without a state license. The stipulated judgment is $2 million, with $375,000 payable to the State and $1.6 million suspended to ensure compliance; the company is barred from specified cannabis activities in Connecticut unless licensed.
$1.1M
Connecticut Attorney General William Tong led a coalition of 45 states and territories seeking court approval for settlements resolving allegations that Ascend Laboratories, Citron Pharma, and Mayne Pharma conspired to inflate prices and limit competition for generic prescription drugs. Ascend agreed to pay $400,000, Mayne agreed to pay $650,000, and Citron’s settlement includes non-monetary terms; the companies also agreed to internal reforms.